ACLARION NEW DL-,00001

Aclarion reports scan‑volume growth of 141% year‑on‑year and 71% sequentially for the first half of 2026, driven by rising adoption of the Nociscan platform. As of 30 June the company had USD 16.3 million in cash and was debt‑free; management says funds will last into H2 2027. Aclarion secured reimbursement from three major UK private insurers (Vitality, Axa, Aviva) and has launched a US market‑access program with PRIA Healthcare. The CLARITY study was expanded and a first interim readout is expected in 2026; the patent portfolio now comprises 65 granted and pending patents worldwide. » More on de.investing.com